Q4 2025 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2026-02-17 · accession 0000905148-26-000841
$216.3M
Reported value
6
Positions
2025-12-31
Period end
The Brief · venBio Partners LLC · Q4 2025
AI · grounded in 13F
venBio Partners LLC reduced its position in Artiva Biotherapeutics Inc ARTV by 43.56%. The fund also trimmed its holding in Lyell Immunopharma Inc LYEL by 28.68%. These moves were part of a broader strategy that saw two positions reduced across a portfolio with $216.3M in total assets under management.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | PHARVARIS N V | $128.7M | 59.5% | 4,639,304 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $45.1M | 20.8% | 4,619,803 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $18.3M | 8.46% | 489,194 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $11.0M | 5.07% | 9,699,925 | Common | SOLE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $10.4M | 4.81% | 337,697 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $2.8M | 1.29% | 648,507 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.